Of those, the NCT04726215 trial that will enrol about 50 non-small cell lung cancer (NSCLC) patients to image T cell activation before and after anti-PD-1/PD-L1 therapy is the largest. The gene discussed is CD274; the disease is non-small cell lung carcinoma.